Summary
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
History
NuCana BioMed is a biopharmaceutical company founded in 2012 with the mission to discover, develop, and commercialize treatments for cancer and rare diseases that have few or no therapeutic options. Headquartered in Edinburgh, Scotland, NuCana has offices in San Francisco, CA and Wilton, CT, and is listed on Nasdaq (NCNA).
Mission
At NuCana, our mission is to discover, develop and commercialize transformative therapies that improve the lives of patients with cancer and rare disorders.
Vision
We believe that by harnessing the power of breakthrough science and technology, we can drive meaningful change in the lives of people living with cancer and rare diseases.
Key Team
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. (Chief Medical Officer)
Prof. Christopher B. Wood FRCS, M.D., Ph.D. (Chief Medical Officer)
Ms. Theresa Bruce (Sr. VP of Clinical Operations)
Ms. Elisabeth Oelmann (Sr. VP of Medical & Clinical Devel.)
Martin Quinn (Company Sec.)
Recognition and Awards
NuCana has been named one of the Fastest Growing Companies in San Francisco by Deloitte's San Francisco Business Times in 2020, as well as to Wired Magazine’s list of 100 Hot Startups to Watch in 2019.
References
